{
  "ticker": "BB1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972580",
  "id": "02972580",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250725",
  "time": "0841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m43ms65m9ydt.pdf",
  "summary": "### **Material Information Summary (ASX:BB1 - Quarterly Activities Report)**  \n\n#### **Clinical & Operational Highlights:**  \n- **U.S. Autism Trial (Pilot Phase)**  \n  - 163 children completed study procedures; 108 enrolled via decentralized recruitment.  \n  - Data unblinding expected in **Q3 2025**, with results shortly after.  \n  - Main Phase enrollment to commence by **end of current quarter** (Q3 2025).  \n\n- **ADHD Trial Expansion (Europe)**  \n  - Expanded from 1 to **5 clinical sites**; ~300 participants expected by year-end.  \n  - Data to support **European regulatory submission (CE marking under EU MDR)**.  \n\n- **IRB Approval for FDA Main Phase**  \n  - Key milestone for **510(k) pathway**; enables Main Phase initiation.  \n\n- **Capital Raising Update**  \n  - **$7.66M raised** (referenced in CEO comments), though not detailed in Appendix 4C.  \n\n#### **Financials (Appendix 4C):**  \n- **Cash Balance (30 June 2025):** **A$8.71M**.  \n- **Net Operating Cash Outflow (Quarter):** **A$1.35M** (R&D: A$0.97M).  \n- **Estimated Funding Runway:** **6.45 quarters** (based on current burn rate).  \n\n#### **Key Catalyst Dates:**  \n- **Q3 2025:** Pilot Phase data unblinding (autism trial).  \n- **Q4 2025:** Expected enrollment completion for ADHD trial (~300 participants).  \n\n### **Omitted:** Non-material operational details, director commentary, and non-financial boilerplate.",
  "usage": {
    "prompt_tokens": 6621,
    "completion_tokens": 364,
    "total_tokens": 6985,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T22:51:03.858410"
}